Opinion|Videos|July 15, 2024
Similarities and Differences Among PSMA-PET Tracers
Author(s)Tony Abraham, DO, MPA
A nuclear radiologist provides an overview of the gallium- and fluorine-based PSMA-PET tracer options, highlighting factors that influence tracer selection.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- There are currently gallium- and fluorine-based PSMA-PET tracer options that are FDA approved. Can you review some of similarities and differences between the gallium and fluorine imaging tracer options identified above in terms of image quality and resolution? And accuracy and false positives?
- Gallium and fluorine tracers also have different half-lives. What does this mean in real-world practice in terms of patient scheduling and preparing for imaging? Can you provide any real-world examples of when one tracer may be preferential over another?
- There are two available F18 tracers available: 18F-Piflufolastat and 18F-Flotufolastat. What are some of the key differences between these? Can you share any examples of differences you’ve seen between these two tracers when used in real-world practice?
Advertisement
Related to this article
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
4
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
5